Baidu
map

Mol. Cell:启动癌细胞对糖嗜好的丙酮酸脱氢酶激酶或为抗癌靶标

2012-01-06 MedSci MedSci原创

癌细胞对糖的渴望,部分上是因为它们关闭它们的线粒体——能够有效燃烧葡萄糖的动力厂——以便偏好一种更加无效率的方式使用葡萄糖。它们获益,因为副产物能够为快速生长的癌细胞提供构建材料。 美国埃默里大学温希普癌症研究所科学家证实很多类型的癌细胞扳动开关让葡萄糖从线粒体转移走。他们的发现提示着促进几种类型癌症生长的酪氨酸激酶在线粒体中发挥的作用要比人们以前所认识的大得多。 这些结果也突出地显示丙酮

癌细胞对糖的渴望,部分上是因为它们关闭它们的线粒体——能够有效燃烧葡萄糖的动力厂——以便偏好一种更加无效率的方式使用葡萄糖。它们获益,因为副产物能够为快速生长的癌细胞提供构建材料。 美国埃默里大学温希普癌症研究所科学家证实很多类型的癌细胞扳动开关让葡萄糖从线粒体转移走。他们的发现提示着促进几种类型癌症生长的酪氨酸激酶在线粒体中发挥的作用要比人们以前所认识的大得多。 这些结果也突出地显示丙酮酸脱氢酶激酶(pyruvate dehydrogenase kinase, PDHK)在控制癌细胞代谢中发挥着重要作用。2011年12月21日,该研究在线发表在《分子细胞》(Molecular Cell)期刊上。 埃默里大学温希普癌症研究所血液学和医学肿瘤学副教授Jing Chen说,“我们和其他人已证实PDHK在人几种类型癌症中上调表达,但是我们发现在癌细胞中存在一种增强PDHK活性的新方法。基于PDHK在调节癌细胞代谢上的作用,PDHK对于抗癌治疗而言是一个非常吸引人的靶标。” Chen和埃默里大学医学院血液学和医学肿瘤学副教授Sumin Kang博士是这篇研究的共同通讯作者。博士后青年Taro

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1868443, encodeId=bd3e1868443b2, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Feb 11 07:21:00 CST 2012, time=2012-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958656, encodeId=e010195865644, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Aug 16 00:21:00 CST 2012, time=2012-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251838, encodeId=e8d5125183833, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sun Jan 08 14:21:00 CST 2012, time=2012-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352683, encodeId=a63f13526836b, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jan 08 14:21:00 CST 2012, time=2012-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495907, encodeId=0e49149590ebf, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Sun Jan 08 14:21:00 CST 2012, time=2012-01-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1868443, encodeId=bd3e1868443b2, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Feb 11 07:21:00 CST 2012, time=2012-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958656, encodeId=e010195865644, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Aug 16 00:21:00 CST 2012, time=2012-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251838, encodeId=e8d5125183833, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sun Jan 08 14:21:00 CST 2012, time=2012-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352683, encodeId=a63f13526836b, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jan 08 14:21:00 CST 2012, time=2012-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495907, encodeId=0e49149590ebf, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Sun Jan 08 14:21:00 CST 2012, time=2012-01-08, status=1, ipAttribution=)]
    2012-08-16 维他命
  3. [GetPortalCommentsPageByObjectIdResponse(id=1868443, encodeId=bd3e1868443b2, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Feb 11 07:21:00 CST 2012, time=2012-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958656, encodeId=e010195865644, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Aug 16 00:21:00 CST 2012, time=2012-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251838, encodeId=e8d5125183833, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sun Jan 08 14:21:00 CST 2012, time=2012-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352683, encodeId=a63f13526836b, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jan 08 14:21:00 CST 2012, time=2012-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495907, encodeId=0e49149590ebf, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Sun Jan 08 14:21:00 CST 2012, time=2012-01-08, status=1, ipAttribution=)]
    2012-01-08 yxch36
  4. [GetPortalCommentsPageByObjectIdResponse(id=1868443, encodeId=bd3e1868443b2, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Feb 11 07:21:00 CST 2012, time=2012-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958656, encodeId=e010195865644, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Aug 16 00:21:00 CST 2012, time=2012-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251838, encodeId=e8d5125183833, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sun Jan 08 14:21:00 CST 2012, time=2012-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352683, encodeId=a63f13526836b, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jan 08 14:21:00 CST 2012, time=2012-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495907, encodeId=0e49149590ebf, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Sun Jan 08 14:21:00 CST 2012, time=2012-01-08, status=1, ipAttribution=)]
    2012-01-08 zhaojie88
  5. [GetPortalCommentsPageByObjectIdResponse(id=1868443, encodeId=bd3e1868443b2, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Feb 11 07:21:00 CST 2012, time=2012-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958656, encodeId=e010195865644, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Aug 16 00:21:00 CST 2012, time=2012-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251838, encodeId=e8d5125183833, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sun Jan 08 14:21:00 CST 2012, time=2012-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352683, encodeId=a63f13526836b, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jan 08 14:21:00 CST 2012, time=2012-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495907, encodeId=0e49149590ebf, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Sun Jan 08 14:21:00 CST 2012, time=2012-01-08, status=1, ipAttribution=)]
    2012-01-08 redcrab

相关资讯

ASCO年度报告:2011临床肿瘤学重大进展之乳腺癌

 AI预防乳腺癌价值获证明   安慰剂对照、双盲乳房预防试验3(NCIC CTG MAP.3)纳入了4560名年龄≥60岁且处于乳腺癌高发危险的绝经后女性。中位随访3年的结果发现,服用芳香化酶抑制剂(AI)依西美坦组女性侵袭性乳腺癌年发生率降低了65%(0.19%对0.55%,P=0.002),同时,癌前病变——导管原位癌的发生率也显著降低;两组临床骨折、骨质疏松症、高胆固醇血症或心血管事件的

Oncotarget:石胆酸能杀死癌细胞但不伤害健康细胞

(LCA抗肿瘤的机制模型:a. 细胞系BE(2)-m17. b. 细胞系SK-n-MCIXC) 2012年1月4日,据《每日科学》报道,在消化过程中由肝脏自然产生,其作用已被严重低估。发表在Oncotarget期刊上的一项研究表明,LCA可以杀死数种类型的癌细胞,如那些发现于脑肿瘤和乳腺癌中的癌细胞。 该研究小组,由Concordia大学领导,同时包括来自麦吉尔大学、蒙特利尔犹太总医院戴维斯研

PNAS:机械挤压作用促进肿瘤转移

(图片来源:PNAS) 麻省理工学院的Janet M. Tse等近日在《美国国家科学院院刊》(Proceedings of the National Academy of Sciences)发表论文称,机械挤压作用或可促进肿瘤细胞转移。 肿瘤细胞在体内进行不受机体控制的增殖分裂,当其分裂数量到达一定程度后,肿瘤细胞便受到有限的空间带来的挤压。为了研究这种挤压作用对肿瘤细胞的影响,Janet T

Science:皮肤中的免疫细胞可产生化学物质促发癌症

在这个表皮表层里,可见朗格汉斯细胞(绿色)构成一个细胞网络,延长树突状的进程 日前,刊登在最新一期Science上的一篇论文"Langerhans Cells Facilitate Epithelial DNA Damage and Squamous Cell Carcinoma"表明,以能探测到皮肤中的外来入侵物而闻名的一组免疫细胞也能通过代谢环境中的化学物质而促进肿瘤的生长。 包括皮肤及

靶向抗癌治疗方法(斯坦福大学公开课)

靶向抗癌治疗方法(斯坦福大学公开课)

ASCO年度报告:2011临床肿瘤学重大进展之黑色素瘤

  BRAF抑制剂改善进展期黑色素瘤患者生存   比较vemurafenib(V600E BRAF抑制剂)与黑色素瘤标准治疗药物达卡巴嗪的Ⅲ期研究纳入675例初治、V600E BRAF基因突变阳性、无法手术的ⅢC或Ⅳ期转移性黑色素瘤患者。   结果显示,48%的vemurafenib组患者肿瘤体积缩小,而达卡巴嗪组仅为5%;与达卡巴嗪组相比,vemurafenib组肿瘤进展风险降低74%,6个

Baidu
map
Baidu
map
Baidu
map